Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.
Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maître A, Pajak TF, Poulsen MG, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP; Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Bourhis J, et al. Among authors: le maitre a. Lancet. 2006 Sep 2;368(9538):843-54. doi: 10.1016/S0140-6736(06)69121-6. Lancet. 2006. PMID: 16950362 Review.
Individual patients' data meta-analyses in head and neck cancer.
Bourhis J, Le Maître A, Baujat B, Audry H, Pignon JP; Meta-Analysis of Chemotherapy in Head, Neck Cancer Collaborative Group; Meta-Analysis of Radiotherapy in Carcinoma of Head, Neck Collaborative Group; Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma Collaborative Group. Bourhis J, et al. Among authors: le maitre a. Curr Opin Oncol. 2007 May;19(3):188-94. doi: 10.1097/CCO.0b013e3280f01010. Curr Opin Oncol. 2007. PMID: 17414635 Review.
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S; Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group. Fizazi K, et al. Among authors: le maitre a. Lancet Oncol. 2007 Nov;8(11):994-1000. doi: 10.1016/S1470-2045(07)70284-X. Epub 2007 Oct 17. Lancet Oncol. 2007. PMID: 17942366
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.
Michiels S, Le Maître A, Buyse M, Burzykowski T, Maillard E, Bogaerts J, Vermorken JB, Budach W, Pajak TF, Ang KK, Bourhis J, Pignon JP; MARCH and MACH-NC Collaborative Groups. Michiels S, et al. Among authors: le maitre a. Lancet Oncol. 2009 Apr;10(4):341-50. doi: 10.1016/S1470-2045(09)70023-3. Epub 2009 Feb 24. Lancet Oncol. 2009. PMID: 19246242
Hyperfractionated or accelerated radiotherapy for head and neck cancer.
Baujat B, Bourhis J, Blanchard P, Overgaard J, Ang KK, Saunders M, Le Maître A, Bernier J, Horiot JC, Maillard E, Pajak TF, Poulsen MG, Bourredjem A, O'Sullivan B, Dobrowsky W, Andrzej H, Skladowski K, Hay JH, Pinto LH, Fu KK, Fallai C, Sylvester R, Pignon JP; MARCH Collaborative Group. Baujat B, et al. Among authors: le maitre a. Cochrane Database Syst Rev. 2010 Dec 8;2010(12):CD002026. doi: 10.1002/14651858.CD002026.pub2. Cochrane Database Syst Rev. 2010. PMID: 21154350 Free PMC article.
Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial.
Jang RW, Le Maître A, Ding K, Winton T, Bezjak A, Seymour L, Shepherd FA, Leighl NB. Jang RW, et al. Among authors: le maitre a. J Clin Oncol. 2009 Sep 10;27(26):4268-73. doi: 10.1200/JCO.2008.20.5815. Epub 2009 Aug 10. J Clin Oncol. 2009. PMID: 19667274 Free PMC article.
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
Goodwin R, Ding K, Seymour L, LeMaître A, Arnold A, Shepherd FA, Dediu M, Ciuleanu T, Fenton D, Zukin M, Walde D, Laberge F, Vincent M, Ellis PM, Laurie SA; from the NCIC Clinical Trials Group, Kingston, Ontario, Canada. Goodwin R, et al. Ann Oncol. 2010 Nov;21(11):2220-2226. doi: 10.1093/annonc/mdq221. Epub 2010 Apr 28. Ann Oncol. 2010. PMID: 20427348 Free article. Clinical Trial.
58 results